Vivosense is pleased to announce that Rob Wilson has joined the company as VP of Marketing Strategy. He brings more than 30 years of expertise in strategic planning, finance, and business development for a wide range of companies in digital health, biotechnology, medical technology, and healthcare service industries.
Wilson shares, "I'm thrilled to announce I have joined VivoSense to help lead marketing strategy! I have known this company for quite some time and am excited to continue to contribute solutions to the evolving digital health landscape."
Vivosense recently completed a $25 Million Series A financing round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund. They’ll use the financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.
“We are excited to welcome Rob to the VivoSense team. Rob’s experience and passion for digital health will help drive VivoSense’s strategy forward developing validated clinical measures and clinical outcome assessments (COAs) for use in registrational studies and FDA regulatory approvals,” Dudley Tabakin, chief executive officer of VivoSense.
Before joining Vivosense, Wilson served as the R&D Business Lead for HealthMode, a digital endpoint development company, and as Sr. VP of Business Development and Corporate Strategy for ActiGraph, a leading provider of wearable activity and sleep monitoring solutions for the global clinical trial and scientific community. He also served as head of healthcare corporate finance and healthcare venture fund relationships at First Union and RBC Capital Markets for the Royal Bank of Canada.
Wilson directed over $3 billion in financing for a wide range of biotech, medical device, and healthcare services companies in these roles. He earned a BS degree from Vanderbilt University and an MBA from the University of Virginia Darden School of Business.
“I am passionate about improving patient clinical research and care,” Wilson says. “Digital health technologies, improved digital biomarkers, and COA provide real-time, real-world evidence that can be extremely important to patients, caregivers, and those involved in the drug development process. I am thrilled to be joining the team at Vivosense and bringing their solutions to market.”